Pulmo BioTech Announces Details Of The Methodology For Its Phase I Human Trials
May 17th, 2008 | by admin |Pulmo BioTech Inc. (OTC Bulletin Board: PLMO.OB) has announced details of the methodology and purpose of its Phase I Human Trials with its PulmoBind Molecular Imaging technology for the diagnosis of Pulmonary Embolism and Pulmonary Hypertension.
The work will be carried out by the Pulmo BioTech subsidiary, PulmoScience Inc., and the title of the work is: “Phase I Study of the Use of PulmoBind for Molecular Imaging of the Pulmonary Circulation.”
The study will be a single center, Phase 1 safety and efficacy study of a single intravenous injection of PulmoBind in human subjects with no history of lung disease.
The Outcomes will be:
1. Safety — to determine pharmacokinetics and biodistribution of PulmoBind in humans and to perform dosimetric evaluation
2. Efficacy — to evaluate the ability of PulmoBind to allow lung perfusion imaging in humans
Pulmo BioTech expects this work to be completed by late summer 2008.
Bookmark It
Hide Sites
Stumble it!